{
    "nctId": "NCT04161833",
    "briefTitle": "Opera\u00ae for Aromatase Inhibitor-related Arthralgia Management (AIA)",
    "officialTitle": "Use of an Alfa-lipoic, Methylsulfonylmethane and Bromelain Dietary Supplement (Opera\u00ae) for Aromatase Inhibitor-related Arthralgia Management (AIA)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hormone Receptor Positive Tumor, Arthralgia",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 53,
    "primaryOutcomeMeasure": "Reduction of AI induced arthralgia at 6 months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older\n* Karnofsky performance score\u226570\n* Indication for AI treatment in adjuvant setting for breast cancer\n* Arthralgia with grade \u22650-1\n\nExclusion Criteria:\n\n* Concomitant diseases, e.g. diabetes, renal insufficiency, alcohol abuse\n* Concomitant rheumatological disease (Rheumatoid arthritis, Spondyloarthropathies, Psoriatic arthritis, etc.)\n* Concomitant endocrinological disease (Acromegaly , Emocromatosis, etc)\n* Any conditions that would complicate arthralgia assessment (e.g. Trauma, Glucocorticoid withdrawal, Hypertrophic osteoarthropathy, Osteoarthritis, Avascular necrosis, Gout, Systemic lupus erythematosus, Septic arthritis, etc.)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}